{Summary}
WHO Position Paper on COVID-19 vaccines– July 2026
Introduction
In accordance with its mandate to provide normative guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers {1} on vaccines and combinations of vaccines against diseases that have an international public health impact.
These papers are concerned primarily with the use of vaccines in large scale vaccination programmes.
The position papers are intended for use by national public health officials and managers of immunization programmes.
They may also be of interest to vaccine advisory groups, international funding agencies, health professionals, researchers, the scientific media, vaccine manufacturers and the general public.
Recommendations on the use of vaccines against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were issued by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization {2} at its meeting in March 2026 and endorsed by WHO thereafter.
Evidence presented at this meeting, as well as SAGE’s conflict of interest assessment, can be accessed at www.who.int/news-room/events/detail/2026/03/09/default-calendar/strategic-advisorygroup-of-experts-on-immunization-march-2026.
The vaccine position papers are developed by the WHO SAGE Secretariat with input from WHO staff at the headquarters and regional levels.
The vaccine position papers summarize essential background information on diseases and vaccines and conclude with the current WHO position on the use of vaccines worldwide.
The position papers are reviewed by a large group of external subject-matter experts and end-users before finalization.
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) and the evidence-to-decision tables are published alongside the position papers.
The methods followed by SAGE {3} and the processes {4} for preparation of vaccine position papers are described on the WHO website.
This position paper is concerned with vaccines and vaccination against COVID-19 and supersedes previous interim guidance issued by WHO on this subject.
Since the WHO declaration of the COVID-19 Public Health Emergency of International Concern (PHEIC) in early 2020, {5} WHO has issued a comprehensive set of strategic and guidance documents to support countries in planning, implementing, monitoring, optimizing and assessing the impact of COVID-19 vaccination.
These included the WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; {6} successive roadmaps to prioritize vaccine use in response to evolving evidence, vaccine supply and epidemiological context; {7} vaccine product-specific and platform interim recommendations for the WHO Emergency Use Listing (EUL) and WHO prequalified COVID-19 vaccines; {8} COVID-19 vaccine delivery guidance, resources and tools; {9} and an overarching global COVID-19 vaccination strategy. {10,11}
In May 2023, WHO announced that COVID-19 no longer constituted a PHEIC due to decreasing trends in COVID-19 deaths and COVID-19-related hospitalizations and intensive care unit (ICU) admissions, and the high levels of populationi mmunityto SARS-CoV-2.{12}
In December 2025, WHO published the Strategic plan for coronavirus disease threat management for the period 2025-2030,{13} which builds on and supersedes previous WHO strategic preparedness and response plans and provides the global framework for the sustained and integrated management of COVID-19 and other coronavirus diseases.
Recommendations in this position paper are provided in the context of Omicron and its sub-lineages being the predominant circulating SARSCoV-2 variant of concern with high population-level immunity to SARS-CoV-2 and the availability of mRNA and protein subunit COVID-19 vaccines.
The recommendations in this position paper will remain valid for new variant-adapted COVID19 vaccines.
They will be revised should new SARS-CoV-2 variants of concern arise, if there are significant changes in COVID-19 epidemiology, or if new evidence indicates that vaccine performance warrants modification of the policy recommendations.
(...)
___
{1} WHO Vaccine Position Papers. Geneva: World Health Organization (www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers (http://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers)).
{2} Strategic Advisory Group of Experts (SAGE) on Immunization. Geneva: World Health Organization (https://www.who.int/groups/strategic-advisory-groupof-experts-on-immunization).
{3} Guidance for the development of evidence-based vaccine-related recommendations. Geneva: World Health Organization; 2017 (www.who.int/publications/m/item/guidance-for-the-development-of-evidence-based-vaccine-related-recommendations).
{4} Supplement to WHO Vaccine Position Papers. Geneva: World Health Organization; 2020 (www.who.int/publications/m/item/who-position-paper-process).
{5} Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019nCoV). Geneva: World Health Organization; 2020 (https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-internationalhealth-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).
{6} WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination Geneva: World Health Organization; 2020 ((https://www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination). Licence: CC BY-NC-SA 3.0 IGO.
{7} WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines. Geneva: World Health Organization; 2023 (https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1). Licence: CC BY-NC-SA 3.0 IGO.
{8} COVID-19 vaccines technical documents Geneva: World Health Organization; 2025 (https://www.who.int/groups/strategic-advisory-group-of-experts-onimmunization/covid-19-materials). Licence: CC BY-NC-SA 3.0 IGO.
{9} COVID-19 vaccine delivery toolkit. Geneva: World Health Organization; 2026 (https://www.who.int/tools/covid-19-vaccine-introduction-toolkit).
{10} Strategy to Achieve Global Covid-19 Vaccination by mid-2022. Geneva: World Health Organization; 2021 (https://www.who.int/publications/m/item/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022).
{11} Global COVID-19 vaccination strategy in a changing world: July 2022 update. Geneva: World Health Organization; 2022 (https://www.who.int/publicatio ns/m/item/global-covid-19-vaccination-strategy-in-a-changing-world--july-2022-update).
{12} Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. Geneva: World Health Organization; 2023 (https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committeeregarding-the-coronavirus-disease-(covid-19)-pandemic).
{13} Strategic plan for coronavirus disease threat management: advancingintegration, sustainability, and equity, 2025–2030. Geneva: WorldHealthOrganization; 2025 (https://www.who.int/publications/i/item/9789240117662). Licence: CC BY-NC-SA 3.0 IGO.
(...)
Source:
Link: https://www.who.int/publications/i/item/who-wer101-30-138-156
____
No comments:
Post a Comment